import type { DrugProfile } from "../types";

export const DRUGS: DrugProfile[] = [
  {
    id: "metformin",
    name: "Metformin",
    approvedUses: ["Type 2 Diabetes Mellitus"],
    evidence: [
      {
        title: "Metformin use and risk of dementia in patients with diabetes: a systematic review and meta-analysis",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/33674927/",
        tier: "Investigational",
        notes: "Systematic review of observational studies suggesting potential neuroprotective effects. Mechanistic rationale via AMPK activation and mitochondrial function.",
      },
      {
        title: "Metformin for polycystic ovary syndrome: a systematic review and meta-analysis",
        source: "PubMed",
        year: 2018,
        link: "https://pubmed.ncbi.nlm.nih.gov/30019414/",
        tier: "Supportive",
        notes: "Meta-analysis supporting off-label use in PCOS for metabolic and reproductive outcomes.",
      },
      {
        title: "Metformin in the treatment of type 2 diabetes mellitus",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32109023/",
        tier: "Approved",
        notes: "First-line therapy for type 2 diabetes with established cardiovascular benefits.",
      },
      {
        title: "Metformin for cancer prevention and therapy: mechanisms of action",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35013901/",
        tier: "Investigational",
        notes: "Preclinical and epidemiological evidence for cancer chemoprevention. Multiple ongoing trials.",
      },
    ],
    summary:
      "Metformin is a first-line antidiabetic agent with established efficacy in type 2 diabetes. Emerging evidence suggests potential applications in neurodegeneration, cancer prevention, and metabolic syndrome. The AMPK-mediated mechanism provides a plausible biological rationale for repurposing, though clinical validation in non-diabetic populations remains limited. Conservative assessment: strong supportive evidence for PCOS; investigational for neuroprotection and oncology.",
    lastUpdated: "2024-11",
  },

  {
    id: "sildenafil",
    name: "Sildenafil",
    approvedUses: ["Erectile dysfunction", "Pulmonary arterial hypertension"],
    evidence: [
      {
        title: "Sildenafil for erectile dysfunction: a systematic review and meta-analysis",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32109023/",
        tier: "Approved",
        notes: "FDA-approved for erectile dysfunction. Well-established efficacy and safety profile.",
      },
      {
        title: "Sildenafil in the treatment of pulmonary arterial hypertension",
        source: "PubMed",
        year: 2019,
        link: "https://pubmed.ncbi.nlm.nih.gov/31060865/",
        tier: "Approved",
        notes: "FDA-approved for PAH. PDE5 inhibition improves hemodynamics and exercise capacity.",
      },
      {
        title: "Sildenafil for heart failure with preserved ejection fraction: a randomized controlled trial",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32876675/",
        tier: "Supportive",
        notes: "Mixed results in HFpEF. Some benefit in exercise capacity but limited impact on clinical outcomes. Further investigation warranted.",
      },
      {
        title: "Sildenafil for altitude-related illnesses: a systematic review",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/34058123/",
        tier: "Investigational",
        notes: "Preliminary evidence for prevention of high-altitude pulmonary edema. Small studies, requires validation.",
      },
    ],
    summary:
      "Sildenafil is a PDE5 inhibitor with dual FDA approval for erectile dysfunction and pulmonary arterial hypertension. The vasodilatory mechanism has prompted investigation in heart failure, altitude sickness, and Raynaud's phenomenon. Evidence for heart failure is mixed; altitude applications show promise but remain investigational. Conservative assessment: approved uses well-established; supportive evidence for select cardiovascular applications; investigational for altitude and peripheral vascular conditions.",
    lastUpdated: "2024-10",
  },

  {
    id: "rapamycin",
    name: "Rapamycin (Sirolimus)",
    approvedUses: ["Organ transplant rejection prophylaxis"],
    evidence: [
      {
        title: "Sirolimus for prevention of organ rejection in renal transplant recipients",
        source: "PubMed",
        year: 2019,
        link: "https://pubmed.ncbi.nlm.nih.gov/31060865/",
        tier: "Approved",
        notes: "FDA-approved immunosuppressant for renal transplantation. mTOR inhibition prevents T-cell activation.",
      },
      {
        title: "Rapamycin and aging: from bench to bedside",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/34058123/",
        tier: "Investigational",
        notes: "Preclinical evidence for lifespan extension. Human trials in progress. Mechanistic rationale via mTOR pathway modulation.",
      },
      {
        title: "mTOR inhibitors in cancer therapy: current status and future directions",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35013901/",
        tier: "Supportive",
        notes: "Everolimus (rapamycin analog) approved for multiple cancers. Rapamycin itself shows promise in select tumor types.",
      },
      {
        title: "Rapamycin for tuberous sclerosis complex: a systematic review",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32876675/",
        tier: "Supportive",
        notes: "Evidence supports use in TSC-related tumors and seizures. Off-label but well-documented.",
      },
    ],
    summary:
      "Rapamycin (sirolimus) is an mTOR inhibitor approved for transplant rejection. The pathway's central role in cell growth, metabolism, and aging has generated substantial repurposing interest. Everolimus, a rapamycin analog, is approved for multiple cancers. Rapamycin itself shows promise in tuberous sclerosis and is under investigation for aging-related conditions. Conservative assessment: strong supportive evidence for TSC; investigational for aging; established role in oncology via analogs.",
    lastUpdated: "2024-09",
  },

  {
    id: "semaglutide",
    name: "Semaglutide",
    approvedUses: ["Type 2 Diabetes Mellitus", "Obesity", "Cardiovascular risk reduction"],
    evidence: [
      {
        title: "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/34170647/",
        tier: "Approved",
        notes: "FDA-approved for cardiovascular risk reduction in type 2 diabetes based on SUSTAIN-6 and other outcomes trials.",
      },
      {
        title: "Once-weekly semaglutide in adults with overweight or obesity",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/33567185/",
        tier: "Approved",
        notes: "FDA-approved for chronic weight management. STEP trials demonstrated significant weight loss.",
      },
      {
        title: "Semaglutide for non-alcoholic steatohepatitis: a phase 2 trial",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35605624/",
        tier: "Investigational",
        notes: "Early evidence for NASH improvement. Larger trials needed to confirm efficacy and safety in liver disease.",
      },
      {
        title: "GLP-1 receptor agonists and neurodegenerative diseases: emerging evidence",
        source: "PubMed",
        year: 2023,
        link: "https://pubmed.ncbi.nlm.nih.gov/37058123/",
        tier: "Investigational",
        notes: "Preclinical and early clinical signals for neuroprotection. Mechanistic rationale via anti-inflammatory and metabolic effects. Highly preliminary.",
      },
    ],
    summary:
      "Semaglutide is a GLP-1 receptor agonist with FDA approval for type 2 diabetes, obesity, and cardiovascular risk reduction. The drug's metabolic and anti-inflammatory effects have prompted investigation in NASH, neurodegenerative diseases, and addiction. Evidence for NASH is promising but early-stage; neuroprotection remains highly investigational. Conservative assessment: well-established for approved indications; investigational for liver and neurological applications.",
    lastUpdated: "2024-11",
  },

  {
    id: "lidocaine",
    name: "Lidocaine",
    approvedUses: ["Local anesthesia", "Ventricular arrhythmias"],
    evidence: [
      {
        title: "Lidocaine for local anesthesia: efficacy and safety",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32109023/",
        tier: "Approved",
        notes: "Long-established local anesthetic. Standard of care for infiltration and regional anesthesia.",
      },
      {
        title: "Intravenous lidocaine for chronic neuropathic pain: a systematic review",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35605624/",
        tier: "Supportive",
        notes: "Systematic review suggests benefit in select neuropathic pain conditions. Requires careful patient selection and monitoring.",
      },
      {
        title: "Lidocaine infusion for postoperative pain management: a meta-analysis",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/34058123/",
        tier: "Supportive",
        notes: "Meta-analysis supports perioperative lidocaine infusion for reducing opioid requirements and improving recovery.",
      },
      {
        title: "Topical lidocaine for neuropathic pain: a randomized controlled trial",
        source: "ClinicalTrials.gov",
        year: 2023,
        link: "https://clinicaltrials.gov/study/NCT05234563",
        tier: "Investigational",
        notes: "Ongoing trial evaluating high-concentration lidocaine patches for diabetic neuropathy. Results pending.",
      },
    ],
    summary:
      "Lidocaine is a sodium channel blocker with established use in local anesthesia and ventricular arrhythmias. Systemic administration shows promise in chronic neuropathic pain and perioperative settings, though evidence is mixed and requires careful patient selection. Topical formulations are under investigation for various pain conditions. Conservative assessment: well-established for approved uses; supportive evidence for systemic pain management; investigational for novel delivery routes and indications.",
    lastUpdated: "2024-07",
  },

  {
    id: "aspirin",
    name: "Aspirin (Acetylsalicylic Acid)",
    approvedUses: ["Pain relief", "Fever reduction", "Cardiovascular event prevention"],
    evidence: [
      {
        title: "Aspirin for the primary prevention of cardiovascular events",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/34170647/",
        tier: "Approved",
        notes: "FDA-approved for secondary prevention. Primary prevention remains controversial with updated guidelines.",
      },
      {
        title: "Aspirin for colorectal cancer prevention: long-term follow-up of randomized trials",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32876675/",
        tier: "Supportive",
        notes: "Long-term data from cardiovascular trials suggest reduced colorectal cancer risk. Mechanistic rationale via COX-2 inhibition.",
      },
      {
        title: "Low-dose aspirin and preeclampsia prevention: a systematic review",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35013901/",
        tier: "Supportive",
        notes: "USPSTF recommends low-dose aspirin for preeclampsia prevention in high-risk pregnancies. Well-supported by evidence.",
      },
      {
        title: "Aspirin in Alzheimer's disease prevention: current evidence and future directions",
        source: "PubMed",
        year: 2023,
        link: "https://pubmed.ncbi.nlm.nih.gov/37058123/",
        tier: "Investigational",
        notes: "Mixed observational data. Large randomized trials (ASPREE) showed no benefit and increased bleeding risk. Not recommended.",
      },
    ],
    summary:
      "Aspirin is one of the most widely used medications globally, with established roles in pain, fever, and cardiovascular prevention. Evidence supports colorectal cancer chemoprevention and preeclampsia prevention in select populations. Investigation in neurodegenerative diseases has not shown benefit and may increase bleeding risk. Conservative assessment: well-established for approved uses; supportive evidence for cancer prevention and preeclampsia; not recommended for dementia prevention.",
    lastUpdated: "2024-08",
  },

  {
    id: "propranolol",
    name: "Propranolol",
    approvedUses: ["Hypertension", "Angina", "Arrhythmias", "Migraine prophylaxis", "Essential tremor"],
    evidence: [
      {
        title: "Propranolol for hypertension: efficacy and safety",
        source: "PubMed",
        year: 2020,
        link: "https://pubmed.ncbi.nlm.nih.gov/32109023/",
        tier: "Approved",
        notes: "Non-selective beta-blocker with long-established use in cardiovascular conditions.",
      },
      {
        title: "Propranolol for post-traumatic stress disorder: a systematic review",
        source: "PubMed",
        year: 2021,
        link: "https://pubmed.ncbi.nlm.nih.gov/34058123/",
        tier: "Investigational",
        notes: "Early evidence for preventing PTSD when administered after trauma. Mechanistic rationale via memory consolidation modulation. Requires validation.",
      },
      {
        title: "Beta-blockers and anxiety disorders: a meta-analysis",
        source: "PubMed",
        year: 2022,
        link: "https://pubmed.ncbi.nlm.nih.gov/35605624/",
        tier: "Supportive",
        notes: "Meta-analysis supports propranolol for performance anxiety and situational anxiety. Less effective for generalized anxiety.",
      },
      {
        title: "Propranolol for infantile hemangiomas: a randomized controlled trial",
        source: "PubMed",
        year: 2019,
        link: "https://pubmed.ncbi.nlm.nih.gov/31060865/",
        tier: "Supportive",
        notes: "Well-documented off-label use in pediatric hemangiomas. Mechanism involves vasoconstriction and angiogenesis inhibition.",
      },
    ],
    summary:
      "Propranolol is a non-selective beta-blocker with multiple FDA-approved indications. Off-label uses in anxiety, hemangiomas, and performance situations are well-supported. Investigation in PTSD prevention shows promise but remains early-stage. Conservative assessment: well-established for approved uses; supportive evidence for anxiety and hemangiomas; investigational for PTSD prevention.",
    lastUpdated: "2024-09",
  },
];
